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Effect of filgotinib on health-related quality of life in
active psoriatic arthritis: a randomized phase 2 trial
(EQUATOR)
Ana-Maria Orbai 1, Alexis Ogdie 2, Laure Gossec 3,4, William Tillett5,6,
Ying Ying Leung7, Jingjing Gao8, Mona Trivedi9, Chantal Tasset10,
Luc Meuleners11, Robin Besuyen12, Thijs Hendrikx13 and Laura C. Coates 14
Abstract
Objective. To examine the effects of filgotinib, an oral, selective Janus kinase 1 inhibitor, on health-related quality of life
(HRQoL) using the Psoriatic Arthritis Impact of Disease (PsAID)9 questionnaire in active PsA.
Methods. Patients were randomized 1 : 1 to filgotinib 200 mg or placebo once daily for 16 weeks in EQUATOR, a
multicentre, double-blind, phase 2 randomized controlled trial. HRQoL was assessed with PsAID9 at Weeks 4 and 16.
Change from baseline in total and individual domain scores, plus the proportions of patients achieving minimal clinically
important improvement (MCII; 53 points) and patient-accepted symptom status (PASS; score <4), were evaluated.
Correlation with the 36-item short-form health survey (SF-36) was investigated.
Results. One hundred and thirty-one patients were randomized to filgotinib or placebo. Filgotinib effects on PsAID9
were observed from Week 4. At Week 16, mean (S.D.) change from baseline in PsAID9 was 2.3 (1.8) and 0.8 (2.2) for
filgotinib and placebo, respectively (least-squares mean of group difference 1.48 [95% CI 2.12, 0.84], P < 0.0001),
with significant improvements in all domains vs placebo. Significantly more patients on filgotinib achieved MCII (group
difference 25.4% [95% CI 8.92, 39.99], P= 0.0022) and PASS (group difference 29.6% [95% CI 10.65, 45.60], P= 0.0018)
at Week 16 vs placebo. Similar improvements in SF-36 were observed, with moderate to strong negative correlation
between PsAID9 and SF-36.
Conclusion. Filgotinib significantly improved HRQoL vs placebo in patients with active PsA, as measured by PsAID9.
To our knowledge, EQUATOR is the first randomized controlled trial to evaluate PsAID9.
Trial registration. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show, NCT03101670.
Key words: clinical trials and methods, DMARDs, outcome measures, quality of life, psoriatic arthritis
Rheumatology key messages
. Psoriatic Arthritis Impact of Disease (PsAID)9 is a validated PsA health-related quality of life instrument.
. Filgotinib significantly improved HRQoL in active PsA in the EQUATOR study, as measured by PsAID9.
. Filgotinib significantly improved PsAID9 total and individual domain scores from Week 4 vs placebo.
Introduction
Psoriatic arthritis (PsA) is an inflammatory musculoskeletal
disease associated with skin and nail psoriasis [1]. PsA
can affect health-related quality of life (HRQoL) in a
number of ways, including through the impact of
symptoms and limitations in physical and social function-
ing and work capacity [2]. Improvement in HRQoL is
therefore an important treatment outcome for patients
with PsA. To date, patient-reported outcomes (PROs)
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developed for other diseases, such as rheumatoid arth-
ritis, or generic measures, including the 36-item short-
form health survey (SF-36), have primarily been used to
assess HRQoL in PsA [3]. Although SF-36 captures infor-
mation on both physical and mental health components
and demonstrates responsiveness to treatment [4, 5], it is
not specific for PsA, the questionnaire is lengthy and the
scoring algorithm complex.
The PsA Impact of Disease (PsAID) is a PRO developed
specifically for use in PsA, in collaboration with patients
and with support from the EULAR. During its develop-
ment, patients with PsA were asked to identify areas of
their health that were impacted by the disease and to
prioritize them according to impact level [6]. Thus, PsAID
measures components of HRQoL perceived to be the
most relevant to patients with PsA, including pain, skin
problems and fatigue [6]. Two versions of the PsAID ques-
tionnaire, PsAID9 and PsAID12, were developed in parallel
and correlate well with each other (PsAID12 contains three
further questions in addition to those included in PsAID9;
comparison shows that similar information is obtained
from both questionnaires at the group level) [6]. Both
have demonstrated good longitudinal construct validity,
reliability and interpretability [7], and demonstrate very
similar testretest reliability (intraclass correlation coeffi-
cient 0.940.95) and internal consistency (Cronbach’s a
0.930.94) [6]. In 2018, the OMERACT initiative provision-
ally endorsed PsAID12 as the first core PRO instrument
for measurement of PsA-related HRQoL in randomized
controlled trials (RCTs) [8, 9]. However, PsAID data from
RCTs investigating drug efficacy are still lacking.
Filgotinib is an oral, selective inhibitor of Janus kinase 1
(JAK1) under development for the treatment of a range of
inflammatory disorders, including PsA, rheumatoid arth-
ritis, ankylosing spondylitis and ulcerative colitis. By
selectively inhibiting the JAK1 signalling protein, filgotinib
reduces the activity of several inflammatory cytokines and
chemokines involved in the pathogenesis of these dis-
eases, as demonstrated in preclinical models [10, 11].
This has translated to a reduction in the signs and symp-
toms of rheumatic diseases in clinical trials [1214]. The
phase 2 EQUATOR study demonstrated significant
improvements across several disease domains in 131
patients with active PsA treated with filgotinib 200 mg
compared with placebo, including peripheral arthritis,
psoriasis, enthesitis and composite disease scores. The
study met its primary endpoint of a significant improve-
ment in ACR20 response rates at Week 16 (filgotinib 80%
vs placebo 33%; treatment difference 47% [95% CI 30.2,
59.6], P < 0.0001). Improvements in PROs relating to
physical functioning, fatigue and pain were also observed,
and filgotinib was well tolerated [12].
Here, we further evaluate the effect of filgotinib vs pla-
cebo on HRQoL in patients who participated in the
EQUATOR study, as measured by PsAID9. To our know-
ledge, EQUATOR is the first RCT to report drug efficacy in
HRQoL using PsAID9, thus also providing valuable infor-
mation on the use of PsAID9 in this setting. Given that
PsAID9 data have not been reported from prior drug
efficacy RCTs in PsA, we also evaluate the effect of filgo-
tinib vs placebo on HRQoL as measured by SF-36, and
provide a comparison of the values obtained using both
instruments.
Methods
Study design and patients
Details of the EQUATOR study (ClinicalTrials.gov identi-
fier: NCT03101670) have been described previously [12].
Briefly, in this multicentre, double-blind, placebo-
controlled, phase 2 study, patients with active PsA
(defined as at least five tender and five swollen joints)
were randomized 1 : 1 to receive filgotinib 200 mg
(Gilead Sciences, Inc., Foster City, CA, USA) or matching
placebo once daily for 16 weeks. Patients were assessed
at Day 1, at Weeks 1, 2, 4, 8, 12, 16 and at a follow-up visit
at Week 20 or 4 weeks following the last dose of study
drug. The protocol was reviewed and approved by the
central or individual independent ethics committees in
each participating country. All patients provided written
informed consent before participation.
Assessments and endpoints
HRQoL was assessed by determining the change from
baseline in PsAID9 and SF-36 scores (with a 1-week
recall period) at Weeks 4 and 16. Data were collected
using an electronic touchscreen version of the question-
naire prior to other study-related procedures at each
study visit. The PsAID9 uses a numerical rating scale
(NRS; range 010; Supplementary Material, Appendix A:
The PsAID9 Questionnaire section, available at
Rheumatology online) to measure nine components of
HRQoL relevant to patients with PsA [6]. Individual items
are prioritized according to the importance of the health
domain each represents. The weight of each domain is
taken into account in the total PsAID score, which is
calculated as follows: (pain NRS value  0.174) + (fatigue
NRS value  0.131) + (skin problems NRS value  0.121)
+ (work and/or leisure activities NRS value  0.110) +
(functional capacity NRS value  0.107) + (discomfort
NRS value  0.098) + (sleep disturbance NRS value 
0.089) + (coping NRS value  0.087) + (anxiety, fear and
uncertainty NRS value  0.085). A higher PsAID score
indicates a greater impact of the disease and poorer
PsA-related HRQoL. Reported endpoints include the
mean change from baseline in PsAID9 total and individual
domain scores at Weeks 4 and 16, the proportions of
patients achieving a minimal clinically important improve-
ment (MCII; defined as a change of three or more points;
only for patients with a baseline score 53), and the pro-
portion of patients achieving a patient-accepted symptom
status (PASS; defined as a PsAID9 score below 4; only for
patients with a baseline score54) at Weeks 4 and 16 [6].
The SF-36 (version 2) consists of 36 questions in eight
health domains. The eight domain scores are summarized
as the Physical Component Summary (PCS) and the
Mental Component Summary (MCS) [5]. The PCS is com-
puted by applying positive coefficients to the physical
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health domains (physical function  0.42, role physical 
0.35, bodily pain  0.32, general health  0.25 and vitality
 0.03), and negative coefficients to the mental health
domains (social functioning  0.01, role emotional 
0.19, mental health  0.22). Comparatively, the MCS
uses positive weights for vitality ( 0.24), social function-
ing ( 0.27), role emotional ( 0.43) and mental health
( 0.49), and negative weights for physical function
( 0.23), role physical ( 0.12), bodily pain ( 0.10)
and general health ( 0.02) [15]. Scores were standar-
dized to a scale of 0100; higher scores indicate better
HRQoL [4]. Subjects with MCS and PCS scores above 50
(in those subjects with a baseline score <50) were classed
as reaching PASS. MCII for both MCS and PCS was
defined as a change of 2.5 or more points for patients
with a baseline score 497.5. Key endpoints included
mean change from baseline in PCS, MCS and in the
eight individual domain scores at Weeks 4 and 16.
Statistical analysis
As previously described, the study sample size was
calculated to be sufficient to detect a treatment
difference for ACR20 response rates at Week 16 (i.e. the
primary endpoint) [12]. All analyses were performed on the
full analysis set, which included all randomized patients who
received at least one dose of study drug. An analysis of
covariance (ANCOVA) model was used to analyse changes
from baseline, with treatment, baseline value and stratifica-
tion factors used at randomization as fixed effects. Adjusted
least-squares (LS) means and 95% CIs within each treat-
ment group and difference between treatment groups were
obtained from the ANCOVA model. Missing values for
change from baseline endpoints were imputed using the
last observation carried forward (LOCF) method.
Proportions of PsAID9 responders were compared between
groups using the Cochran-Mantel-Haenszel test, controlling
for randomization stratification factors, and summarized
with a point estimate and 95% CIs using the Newcombe
method. Missing data for response endpoints were handled
using the non-responder imputation method. Pearson’s
correlations were calculated to investigate the relationship
between the change from baseline in PsAID9 and SF-36
PCS and MCS scores at Weeks 4 and 16. A correlation
coefficient of 0.400.59 was considered as moderate, and
a coefficient of 0.600.79 was considered as strong [16].
SAS

software, version 9.4 (SAS Institute Inc., Cary, NC,
USA) was used to perform all statistical analyses.
Results
Patients
Of the 131 patients enrolled in the study, 65 were
randomized to receive filgotinib 200 mg and 66 to receive
placebo once daily. Demographics and baseline disease
characteristics, which have been reported in detail previ-
ously [12], were generally balanced across treatment
groups and consistent with PsA populations in other
PsA studies. A total of 20 patients (filgotinib 11/65
[17%]; placebo 9/66 [14%]) had received prior anti-TNF-
a therapy. Mean (S.D.) PsAID9, SF-36 PCS and MCS
scores at baseline were similar between the filgotinib
and placebo groups, respectively (PsAID9: 5.8 [1.6] vs
5.7 [2.0]; SF-36 PCS: 35.2 [5.9] vs 36.3 [7.0]; SF-36
MCS: 42.9 [11.6] vs 42.8 [11.4]).
PsAID9
All patients provided evaluable data for PsAID9. Filgotinib
significantly improved PsAID9 total score compared with
placebo. Mean change (S.D.) from baseline in PsAID9 at
FIG. 1 Change from baseline in (A) PsAID9 total, (B) SF-36
PCS and (C) SF-36 MCS scores (LOCF; FAS)
Data shown are mean (S.D.). **P < 0.01, ***P < 0.001
(between-group differences, calculated from an ANCOVA
model). ANCOVA: analysis of covariance; FAS: full ana-
lysis set; LOCF: last observation carried forward; MCS:
Mental Component Summary; PCS: Physical Component
Summary; PsAID: Psoriatic Arthritis Impact of Disease;
SF-36: 36-item short-form health survey.
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Week 4 was 1.9 (1.6) and 0.5 (1.8) in the filgotinib and
placebo groups, respectively (LS mean difference 1.45
[95% CI 2.02, 0.89], P < 0.0001), and at Week 16 was
2.3 (1.8) and 0.8 (2.2), respectively (1.48 [95% CI 2.12,
0.84], P < 0.0001) (Fig. 1A). Significant improvements
were observed in all individual PsAID domains at Week
16, and in all but one domain (anxiety, fear, uncertainty)
as early as Week 4 (Table 1 and Supplementary Table S1,
available at Rheumatology online; Fig. 2A and B). Absolute
PsAID9 total and individual domain scores at Week 4 and
16 are shown in Supplementary Table S2, available at
Rheumatology online.
Significantly more patients receiving filgotinib achieved
MCII in PsAID9 total score compared with placebo at
Week 4 (26.2% vs 8.6%, respectively; treatment differ-
ence 17.6% [95% CI 3.87, 30.76]; P= 0.0076) and at
Week 16 (42.6% vs 17.2%; treatment difference 25.4%
[95% CI 8.92, 39.99]; P= 0.0022) (Fig. 3A and B). This
also held true if alternative MCII definitions (of a change
of 51.25 or 53.6 points) were used (Fig. 3A and B). In
addition, a greater proportion of patients on filgotinib
achieved PASS in PsAID9 at both Week 4 (42.6% vs
16.0%; treatment difference 26.6% [95% CI 9.07,
41.89]; P= 0.0019) and Week 16 (55.6% vs 26.0%; treat-
ment difference 29.6% [95% CI 10.65, 45.60]; P= 0.0018),
compared with placebo (Fig. 3C; Table 1).
SF-36
Filgotinib significantly improved the SF-36 PCS score
compared with placebo at Weeks 4 and 16 (Table 2 and
Supplementary Table S3, available at Rheumatology
online). Mean change (S.D.) from baseline at Week 4 was
4.9 (5.9) and 1.5 (6.2) in the filgotinib and placebo groups,
respectively (LS mean difference 3.08 [95% CI 1.14, 5.02],
P= 0.0021), and at Week 16 was 7.4 (6.6) and 2.4 (6.6),
respectively (4.67 [95% CI 2.58, 6.76], P < 0.0001)
(Fig. 1B). Significant improvements were observed in all
individual SF-36 physical health domains at Week 16, and
in all but one domain (general health) as early as Week 4
(Table 2 and Supplementary Table S3, available at
Rheumatology online; Fig. 2C and D). No significant
improvement was observed in the SF-36 MCS score in
the filgotinib group compared with placebo at Weeks 4
or 16 (Table 2 and Supplementary Table S3, available at
Rheumatology online; Fig. 1C). Significantly more patients
receiving filgotinib achieved MCII for PCS compared with
TABLE 1 Change from baseline in PsAID9 total and individual domain scores (LOCF; FAS), standardized response mean
(LOCF; FAS) and proportion of patients achieving MCII and PASS (NRI; FAS) at Week 16
Filgotinib (n = 65) Placebo (n = 66) Treatment differencea P-valueb
PsAID9 total score 2.3 (1.8) 0.8 (2.2) 1.48 <0.0001
(2.12, 0.84)
Pain 2.9 (2.2) 0.9 (2.6) 1.75 <0.0001
(2.45, 1.05)
Fatigue 2.3 (2.0) 0.8 (2.7) 1.45 <0.0001
(2.18, 0.73)
Skin problems 2.1 (2.4) 0.4 (2.6) 1.68 <0.0001
(2.40, 0.95)
Work and/or leisure activities 2.4 (2.3) 0.9 (2.9) 1.51 0.0002
(2.30, 0.73)
Functional capacity 2.4 (2.1) 0.7 (2.7) 1.61 <0.0001
(2.35, 0.87)
Discomfort 2.4 (2.3) 1.1 (2.6) 1.36 0.0005
(2.11, 0.61)
Sleep disturbances 1.9 (2.4) 1.0 (2.9) 1.28 0.0025
(2.10, 0.46)
Coping 2.1 (2.3) 1.1 (2.5) 1.12 0.0025
(1.85, 0.40)
Anxiety, fear, uncertainty 1.8 (2.4) 0.8 (2.4) 0.95 0.0155
(1.71, 0.18)
Standardized response mean 1.3 0.4  
Filgotinib (n= 61) Placebo (n= 58) Treatment differencec P-valued
Proportion of patients achieving MCIIe, % 42.6 17.2 25.4 (8.92, 39.99) 0.0022
Filgotinib (n= 54) Placebo (n= 50) Treatment differencec P-valued
Proportion of patients achieving PASSf, % 55.6 26.0 29.6 (10.65, 45.60) 0.0018
Data shown are mean (S.D.), unless otherwise indicated. aFilgotinib vs placebo. LS mean of group difference (95% CI).
bBetween-group P-value was calculated from an ANCOVA model on the changes from baseline per visit, with treatment,
baseline values and randomization stratification factors. cFilgotinib vs placebo. Difference (95% CI). dBetween-group P-value
was calculated from Cochran-Mantel-Haenszel test controlling for randomization stratification factors. eMCII defined as a
change of 53 points; only for patients with a baseline score 53. fPASS defined as total score of <4; only for patients
with a baseline score 54. ANCOVA: analysis of covariance; FAS: full analysis set; LOCF: last observation carried forward; LS:
least-squares; MCII: minimal clinically important improvement; NRI: non-responder imputation; PASS: patient-acceptable
symptom state; PsAID: Psoriatic Arthritis Impact of Disease.
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placebo at Week 4 (60.0% vs 36.4%; treatment difference
23.6% [95% CI 6.52, 38.60], P= 0.0081) and Week 16
(75.4% vs 39.4%; treatment difference 36.0% [95% CI
19.20, 50.03], P < 0.0001). Significantly more patients
achieved PCS PASS at Week 16 in the filgotinib vs pla-
cebo groups (17.2% vs 6.3%; treatment difference 10.9%
[95% CI 0.66, 22.52], P = 0.0471; Table 2). No statistic-
ally significant treatment differences were seen for MCII in
MCS or for MCS PASS rates (Table 2). Absolute PCS,
MCS and individual SF-36 domain scores at Weeks 4
and 16 are shown in Supplementary Table S4, available
at Rheumatology online.
Correlation between PsAID9 and SF-36
Moderate to strong negative, statistically significant cor-
relations were observed between PsAID9 and both SF-36
PCS and MCS scores at Weeks 4 and 16 in both treat-
ment groups (Fig. 4; at Week 16, the Pearson’s correl-
ation coefficient for SF-36 PCS and PsAID9 was 0.63
[P < 0.0001] for filgotinib and 0.63 [P < 0.0001] for pla-
cebo. For MCS and PsAID9, correlation coefficients were
0.60 [P < 0.0001] for filgotinib and 0.41 [P= 0.0009] for
placebo). The standardized response mean for filgotinib
was numerically greater, but not statistically significant,
for PsAID9 than for SF-36 PCS or MCS scores (Tables 1
and 2 and Supplementary Table S5, available at
Rheumatology online).
Discussion
Compared with placebo, filgotinib significantly improved
HRQoL in patients with active PsA in the phase 2
EQUATOR study, as measured by PsAID9. This is in
line with the primary clinical outcomes of the study [12].
Improvements in the PsAID9 total score and in all indi-
vidual domains were evident by Week 16 (the primary
study assessment timepoint), and in eight of the nine in-
dividual domains as early as Week 4 (the earliest assess-
ment timepoint). This suggests that, in this study,
filgotinib had a rapid effect on the multiple aspects of
HRQoL that are relevant to patients with active PsA.
Various values have been proposed to define a MCII for
PsAID9 [17]. Therefore, the proportion of responders
were presented based on three thresholds (a change of
51.25, 53 or 53.6 points). The proportion of
responders varied depending on the definition used but
was consistently greater in filgotinib-treated patients
than in the placebo group. Further research is required
to confirm the most appropriate threshold value to use
for PsAID9.
The PsAID9 domain that was not significantly
improved at Week 4 (anxiety, fear, uncertainty) may
FIG. 2 Mean absolute scores in individual domains of PsAID9a (A and B) and SF-36b (C and D) (LOCF; FAS)
aHigher PsAID9 scores are worse and correspond to poorer PsA-specific HRQoL. bHigher SF-36 scores correspond to
better HRQoL. *P < 0.05, ** P < 0.01, *** P < 0.001 (between-group differences in change from baseline scores at Week
16, calculated from an ANCOVA model). ANCOVA: analysis of covariance; FAS: full analysis set; HRQoL: health-related
quality of life; LOCF: last observation carried forward; PsAID: Psoriatic Arthritis Impact of Disease; SF-36: 36-item short-
form health survey.
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take longer to show improvement than musculoskeletal
disease manifestations and impact. Although improve-
ments in all SF-36 physical health domains were noted
at Week 16 with filgotinib vs placebo, there was no sig-
nificant improvement in the SF-36 MCS score. This is not
unusual, however, as the negative weighting of the
physical health components makes it more difficult to
show change in the MCS score [15]. Another potential
contributing factor is the study powering and sample
size; these were calculated for the primary efficacy end-
point (ACR20 response rate at Week 16) only. In addition,
we found that the standardized response mean for filgo-
tinib was numerically greater for PsAID9 than SF-36,
possibly suggesting that PsAID9 is more sensitive to
change than SF-36 scores.
A limitation of the current study is the mixed popula-
tion of anti-TNF-a therapy-naı¨ve and exposed patients,
although this is reflective of the population encountered
in usual clinical practice. Unfortunately, the relatively
small sample sizes in each of these subgroups meant
that analysis according to prior anti-TNF-a therapy
exposure was not feasible. The number of subjects is
in line with what would be expected in a phase 2 study
of this nature, and the study population was consistent
with that of other studies in patients with PsA, with
respect to baseline HRQoL [6, 1719]. LOCF was used
to impute missing data, hence further analyses might be
needed to understand the impact of missing data on
PsAID9.
To our knowledge, EQUATOR is the first RCT from
which PsAID9 efficacy data have been reported, thus pro-
viding key information regarding the potential utility of this
disease-relevant PRO. Improvements in PsAID9 total
score for filgotinib vs placebo were reflected in improve-
ments in each individual PsAID9 domain by Week 16. We
have also shown that PsAID9 correlates well with both
physical and mental health components of the generic
SF-36 survey in this setting. The correlation was stronger
and more linear with PCS vs MCS, possibly reflecting
better alignment of domain content and weighting
between PsAID9 and PCS. This concurs with observa-
tions from validation studies of the PsAID questionnaires
[6, 17]. In these studies, which involved patients
across multiple centres and countries [20], individual
PsAID domains were found to correlate strongly with rele-
vant clinical outcomes and PROs, i.e. the fatigue domain
correlates with scores from the Functional Assessment of
Chronic Illness Therapy-Fatigue tool and the skin domain
with Dermatology Quality of Life Index, with PsAID9 and
PsAID12 performing similarly [17]. In a post-hoc analysis
of a preliminary PsAID validation study, PsAID domains
had stronger correlations with patient-perceived global
assessments than with other PROs or physician-based
assessments [18]. The 9- and 12-item PsAID question-
naires have comparable correlation with other measures
of health status [6].
The importance of patient involvement in the manage-
ment of disease is widely recognized as a means of
empowering patients and improving both outcomes and
the quality of care [21, 22]. Assessing PROs, such as
HRQoL, in addition to acute disease activity measures is
essential to fully appreciate the true impact of disease and
can aid the clinical decision-making process [23].
Similarly, collection of HRQoL data in clinical trials of
drugs in development for the treatment of PsA is essential
FIG. 3 Proportions of patients achieving (A) MCIIa in
PsAID9 score at Week 4, (B) MCIIa in PsAID9 score at
Week 16 and (C) PASSb in PsAID9 score at Week 4 and 16
(NRI; FAS)
aMCII defined as a change 51.25, 53 or 53.6 points.
bPASS defined as total score <4. *P < 0.05, **P < 0.01,
***P < 0.001 (between-group differences in MCII or PASS,
calculated from Cochran-Mantel-Haenszel test). FAS: full
analysis set; MCII: minimal clinically important improve-
ment; NRI: non-responder imputation; PASS: patient-
acceptable symptom state; PsAID: Psoriatic Arthritis
Impact of Disease.
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to confirm that improvements in clinical endpoints trans-
late to improvements in patient well-being. Research into
the best way to assess these factors is still required [2,
24]; however, PsAID may potentially provide the means to
do so. PsAID9 assesses the impact of multiple disease
domains (pain, fatigue, skin and physical function) that
are included in OMERACT’s PsA Core Domain Set,
which aims to standardize the measurement and reporting
of outcomes across PsA clinical studies [24, 25]. PsAID9
also assesses the impact of disease on emotional and par-
ticipation factors, which have been identified by patients
as important components of HRQoL, although not cur-
rently part of the Core Domain Set [24, 26, 27]. The as-
sessment of multiple patient-relevant HRQoL domains in
one PRO using only nine questions is a key advantage to
PsAID9, making its use more feasible in trials and clinical
practice than more complex generic tools, such as SF-36.
The electronic touchscreen version of PsAID, which was
used in this trial, has shown a high degree of correlation to
the pencil and paper version. It was also preferred by pa-
tients and took less time to complete than the pencil and
paper version [19]. Such innovations may further facilitate
the incorporation of PsAID into future trials and clinical
practice.
In conclusion, to our knowledge the phase 2 EQUATOR
study is the first RCT in patients with active PsA to report
PsAID9 data. Filgotinib significantly improved total scores
and scores in each of the nine PsAID9 domains, vs pla-
cebo, in patients with active PsA and effects were seen
from Week 4. Significantly more patients achieved PsAID9
MCII and PASS at Week 16 with filgotinib vs placebo.
These data also support the use of PsAID9 in measuring
TABLE 2 Change from baseline in SF-36 scores (LOCF; FAS), standardized response mean (LOCF; FAS) and proportion
of patients achieving MCII and PASS (NRI; FAS) at Week 16
Filgotinib (n=65) Placebo (n=66) Treatment differencea P-valueb
PCS 7.4 (6.6) 2.4 (6.6) 4.67 <0.0001
(2.58, 6.76)
MCS 4.3 (8.3) 3.2 (9.2) 1.19 0.4128
(1.67, 4.04)
General health 5.8 (7.3) 2.8 (6.3) 3.00 0.0118
(0.68, 5.32)
Role physical 5.6 (6.7) 3.0 (6.4) 2.60 0.0131
(0.56, 4.65)
Physical functioning 8.4 (7.2) 3.0 (7.9) 5.15 <0.0001
(2.69, 7.62)
Bodily pain 8.0 (7.2) 2.0 (7.6) 5.15 <0.0001
(2.97, 7.33)
Vitality 6.3 (7.7) 2.9 (7.2) 3.35 0.0072
(0.92, 5.77)
Mental health 5.5 (7.5) 2.6 (8.6) 2.96 0.0283
(0.32, 5.60)
Role emotional 5.5 (10.8) 4.1 (9.8) 1.18 0.4559
(1.95, 4.31)
Social functioning 4.8 (9.2) 3.0 (9.1) 1.94 0.1516
(0.72, 4.59)
Standardized response mean
PCS 1.1 0.4  
MCS 0.5 0.3  
Proportion of patients achieving MCIIe, %
PCS 75.4 39.4
Treatment differencec
36.0 (19.20, 50.03)
P-valued
<0.0001
MCS 49.2 60.6 11.4 (27.41, 5.53) 0.2607
Proportion of patients achieving PASSf, %
PCS 17.2 6.3
Treatment differencec
10.9 (0.66, 22.52)
P-valued
0.0471
MCS 28.3 29.8 1.5 (19.44, 16.59) 0.9879
Data shown are mean (S.D.), unless otherwise indicated. aFilgotinib vs placebo. LS mean of group difference (95% CI).
bBetween-group P-value was calculated from an ANCOVA model on the changes from baseline per visit, with treatment,
baseline values and randomization stratification factors. cFilgotinib vs placebo. Difference (95% CI). dBetween-group P-value
was calculated from Cochran-Mantel-Haenszel test controlling for randomization stratification factors. eMCII for both MCS and
PCS was defined as a change of 2.5 or more points, for patients with a baseline score 497.5. fPASS for both MCS and PCS
was defined as a MCS/PCS score above 50 (in those subjects with a baseline score <50). ANCOVA: analysis of covariance;
FAS: full analysis set; LOCF: last observation carried forward; LS: least-squares; MCII: minimal clinically important improve-
ment; MCS: Mental Component Summary; NRI: non-responder imputation; SF-36: 36-item short-form health survey; PASS:
patient-acceptable symptom state; PCS: Physical Component Summary.
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patient-relevant HRQoL domains in PsA clinical studies. A
long-term, open-label extension of EQUATOR is ongoing
(NCT03320876).
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